Skip to content
Search

Latest Stories

3 in 5 cancer patients in England now diagnosed at early stage - NHS analysis

Early cancer diagnosis in England has reached its highest level ever.
Colon cancer blood test, conceptual image. (gettyimages)

The TLHC programme led to the earlier diagnosis of over 5,000 people with lung cancer since its launch in 2019

More cancers are being detected earlier in England, thanks to a major drive by the NHS encouraging people, particularly those at higher risk due to hereditary or lifestyle factors, to come forward for potentially life-saving screenings.

According to a new NHS analysis, early cancer diagnosis in England has reached its highest level ever.


The NHS data of the most common cancers, including breast, prostate, and lung cancer, shows that almost three in five patients are now being diagnosed at stages one or two, when the cancer is more treatable.

More than 58 per cent of all common cancers (206,038) diagnosed between September 2023 and August 2024 were identified at an early stage.

This marks a 2.7 percentage point improvement compared to pre-pandemic levels, equating to an estimated 7,000 more patients being diagnosed at an early stage.

The NHS has introduced initiatives like the Targeted Lung Health Check (TLHC) and Liver Health Programmes to detect cancers earlier.

These programmes use mobile scanning trucks and vans that go into the heart of communities, offering in-depth checks to people at shopping centres, sports stadiums, food banks and supermarket car parks.

Since its launch in 2019, the TLHC programme has led to the earlier diagnosis of over 5,000 people with lung cancer, NHSE data reveals.

“Lives are saved when cancers are caught early,” said Dame Cally Palmer, national cancer director for NHS England, highlighting the benefits of the early cancer detection drive.

“There is still much more to do to save more lives and we will not let up in our efforts to catch more cancers earlier, where treatment is more likely to be successful.”

“NHS teams across the country are continuing to take tests and checks closer to people who need them, and with new treatments being made available all the time, we will continue to do all we can to get people seen and treated for cancer as early as possible,” he added.

Professor Peter Johnson, NHS England’s national clinical director for cancer, noted that as life expectancy increases and the number of people developing cancer continues to rise, the NHS diagnosing more cancers than ever before.

He encourages people who suspect they might have signs or symptoms of cancer to get checked so that they can get treatment promptly.

According to Cancer Research UK, lung cancer is the most common cause of cancer death in the UK, accounting for about 21 per cent of all cancer deaths in females and males combined (2017-2019). The next most common causes of cancer death are bowel cancer (10 per cent ), followed by prostate cancer, and breast cancer (both responsible for about seven per cent of all cancer fatalities).

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less